• Cenk Sunu, Ahmet Kursad Gunes, Gulten Korkmaz Akat, Yasin Kalpakci, Funda Ceran, Simten Dagdas, and Gulsum Ozet.
• Sakarya University Training and Research Hospital, Department of Hematology - Sakarya, Turkey.
• Rev Assoc Med Bras (1992). 2021 Mar 1; 67 (3): 385-389.

ObjectiveThe aim of this study was to compare the incidence of factors associated with an increased risk of thrombosis in patients with essential thrombocythemia.MethodsA total of 200 patients followed-up in our unit with a diagnosis of essential thrombocythemia in 13 years were analyzed retrospectively.ResultsOf the study participants, 60.5% were females and 39.5% were males, with an overall mean (±SD) age of 54.93 (±14.21) years. In 119 patients, Janus Kinase 2 was positive with 56.3% of cases. When two patient categories were defined as those with or without history of thrombosis, no significant differences were found in terms of Janus Kinase 2 positivity, mean age, as well as white blood cells and platelet counts (p>0.05). Also, no significant differences in thrombotic event incidence were found between patient categories defined on the basis of cut-off values for white blood cells (cut-off values of 15×103/mm3 and 8.7×103/mm3) and platelets (cut-off values of 1500×103/mm3) (p>0.05).ConclusionAlthough our results are generally in line with the published data, some divergence from previous results has been observed with respect to risk factors for thrombotic events. Absence of a correlation between leukocytosis and thrombosis may be related with the significant decline in white blood cells after treatment. Also, a significant reduction in platelet counts occurring in association with treatment is linked with a lowered incidence of thrombosis. Janus Kinase 2-positive patients had a similar thrombosis frequency with that reported in the literature.

17 keywords...

hide…